Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
Johanna S. Enke, MD
Advertisement
Articles by Johanna S. Enke, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Investigating Novel Immunotherapy Targets in Metastatic RCC
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
5